TY - JOUR
T1 - Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology :
T2 - Implementation and Clinical Validation
AU - Calvo Lozano, Olalla
AU - Sierra, Miquel
AU - Soler Aznar, Maria
AU - Estévez, M. Carmen
AU - Chiscano-Camón, Luis
AU - Ruiz-Sanmartin, Adolfo
AU - Ruiz-Rodriguez, Juan Carlos
AU - Ferrer, Ricard
AU - González-López, Juanjo
AU - Esperalba, Juliana
AU - Fernandez-Naval, Candela
AU - Bueno, Leticia
AU - López-Aladid, Ruben
AU - Torres, Antoni
AU - Fernández-Barat, Laia
AU - Attoumani, Sarah
AU - Charrel, Rémi
AU - Coutard, Bruno
AU - Lechuga, Laura M
PY - 2022
Y1 - 2022
N2 - Serological tests are essential for the control and management of COVID-19 pandemic (diagnostics and surveillance, and epidemiological and immunity studies). We introduce a direct serological biosensor assay employing proprietary technology based on plasmonics, which offers rapid (<15 min) identification and quantification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in clinical samples, without signal amplification. The portable plasmonic device employs a custom-designed multiantigen (RBD peptide and N protein) sensor biochip and reaches detection limits in the low ng mL -1 range employing polyclonal antibodies. It has also been implemented employing the WHO-approved anti-SARS-CoV-2 immunoglobulin standard. A clinical validation with COVID-19 positive and negative samples (n = 120) demonstrates its excellent diagnostic sensitivity (99%) and specificity (100%). This positions our biosensor as an accurate and easy-to-use diagnostics tool for rapid and reliable COVID-19 serology to be employed both at laboratory and decentralized settings for the disease management and for the evaluation of immunological status during vaccination or treatment.
AB - Serological tests are essential for the control and management of COVID-19 pandemic (diagnostics and surveillance, and epidemiological and immunity studies). We introduce a direct serological biosensor assay employing proprietary technology based on plasmonics, which offers rapid (<15 min) identification and quantification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in clinical samples, without signal amplification. The portable plasmonic device employs a custom-designed multiantigen (RBD peptide and N protein) sensor biochip and reaches detection limits in the low ng mL -1 range employing polyclonal antibodies. It has also been implemented employing the WHO-approved anti-SARS-CoV-2 immunoglobulin standard. A clinical validation with COVID-19 positive and negative samples (n = 120) demonstrates its excellent diagnostic sensitivity (99%) and specificity (100%). This positions our biosensor as an accurate and easy-to-use diagnostics tool for rapid and reliable COVID-19 serology to be employed both at laboratory and decentralized settings for the disease management and for the evaluation of immunological status during vaccination or treatment.
KW - Immunology
KW - Sensors
KW - Peptides and proteins
KW - Assays
KW - Biopolymers
U2 - 10.1021/acs.analchem.1c03850
DO - 10.1021/acs.analchem.1c03850
M3 - Article
C2 - 34971311
SN - 0003-2700
VL - 94
SP - 975
EP - 984
JO - Analytical Chemistry
JF - Analytical Chemistry
ER -
